Researchers at the CU Anschutz Cancer Center have launched a clinical trial funded by the National Cancer Institute that will ...

Although bladder cancer ranks as the sixth most common cancer in the United States, with approximately 85,000 new cases diagnosed each year, it continues to receive limited awareness, advocacy, and ...

A new Stanford Medicine study reveals that colorblind men face 52% higher bladder cancer death risk because they can't see ...

Signatera detects molecular residual disease in bladder cancer by identifying tumor DNA fragments in the bloodstream, even when not visible on scans. The IMvigor010 trial showed that Signatera-guided ...

Cellens, a Boston, MA-based cancer diagnostics startup, has raised a $6.5 million seed round. The company is developing a mechanobiology and AI-driven platform, BioFeel, for non-invasive cancer ...

Natera NTRA recently announced the submission of a premarket approval (PMA) application to the FDA for its Signatera CDx test ...

BOSTON, MA, UNITED STATES, December 23, 2025 /EINPresswire.com/ -- Cellens, Inc., a cancer diagnostics company pioneering a new mechanobiology and AI-driven platform ...

Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.71. BERLIN — For years, scientists have held out hope that tests that look ...

Nearly 20,000 women are diagnosed with bladder cancer each year, according to the American Cancer Society, with most being over age 55. And the unfortunate reality is that women are often diagnosed at ...

Researchers at the University of Birmingham believe that a simple urine test could help to guide clinicians in the treatment of bladder cancer patients. Being able to reliably identify those patients ...

Inlexzo is a new treatment for a type of bladder cancer in adults that hasn’t spread to the muscles and doesn’t respond to Bacillus Calmette-Guérin (BCG) therapy. It’s approved for treating non-muscle ...